Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Precision Medicine in Oncology Podcast Series: Ep7. Importance of Genetic Testing in Patients with Prostate Cancer

23:31
 
Share
 

Manage episode 308241201 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests.

Our guest:
Our guest on today’s episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

  continue reading

71 episodes

Artwork
iconShare
 
Manage episode 308241201 series 2812899
Content provided by IMPACT Medicom. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by IMPACT Medicom or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

In this seventh episode of our podcast series on precision medicine, hosted by Anna Christofides, we discuss genomic testing in prostate cancer. Our episode focuses on the evolution and uptake of genetic testing in prostate cancer. We discuss testing for homologous recombination repair (HRR) genes and their association with prognosis and influence on treatment decisions. We also discuss somatic vs germline testing and who is responsible for ordering genomic tests.

Our guest:
Our guest on today’s episode is Dr. Neil Fleshner, who is the Martin Barkin Chair and a Professor of Surgery at the Division of Urology at the University of Toronto in Toronto, Ontario. He is also affiliated with Sunnybrook Hospital, Mount Sinai Hospital, Princess Margaret Cancer Centre (UHN), and the Toronto General Hospital (UHN).
This podcast episode was sponsored by AstraZeneca Canada and Merck Canada.
If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

  continue reading

71 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play